These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8527002)

  • 1. Effect of age and disease duration on parkinsonian motor scores under levodopa therapy.
    Ransmayr G; Künig G; Neubauer M; Wagner M; Falk M
    J Neural Transm Park Dis Dement Sect; 1995; 9(2-3):177-88. PubMed ID: 8527002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa.
    Schaafsma JD; Giladi N; Balash Y; Bartels AL; Gurevich T; Hausdorff JM
    J Neurol Sci; 2003 Aug; 212(1-2):47-53. PubMed ID: 12809998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
    Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
    J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The patient's perspective: The effect of levodopa on Parkinson symptoms.
    Zach H; Dirkx M; Pasman JW; Bloem BR; Helmich RC
    Parkinsonism Relat Disord; 2017 Feb; 35():48-54. PubMed ID: 27919585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical correlates of action tremor in Parkinson disease.
    Louis ED; Levy G; Côte LJ; Mejia H; Fahn S; Marder K
    Arch Neurol; 2001 Oct; 58(10):1630-4. PubMed ID: 11594921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
    Marsden CD
    Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa changes the severity of freezing in Parkinson's disease.
    Fietzek UM; Zwosta J; Schroeteler FE; Ziegler K; Ceballos-Baumann AO
    Parkinsonism Relat Disord; 2013 Oct; 19(10):894-6. PubMed ID: 23642712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation.
    Bejjani BP; Gervais D; Arnulf I; Papadopoulos S; Demeret S; Bonnet AM; Cornu P; Damier P; Agid Y
    J Neurol Neurosurg Psychiatry; 2000 May; 68(5):595-600. PubMed ID: 10766889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical predictive factors of subthalamic stimulation in Parkinson's disease.
    Welter ML; Houeto JL; Tezenas du Montcel S; Mesnage V; Bonnet AM; Pillon B; Arnulf I; Pidoux B; Dormont D; Cornu P; Agid Y
    Brain; 2002 Mar; 125(Pt 3):575-83. PubMed ID: 11872614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease.
    Chastan N; Westby GW; Yelnik J; Bardinet E; Do MC; Agid Y; Welter ML
    Brain; 2009 Jan; 132(Pt 1):172-84. PubMed ID: 19001482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease.
    Bonuccelli U; Del Dotto P; Lucetti C; Petrozzi L; Bernardini S; Gambaccini G; Rossi G; Piccini P
    Clin Neuropharmacol; 2000; 23(1):28-33. PubMed ID: 10682228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal Olfaction in Parkinson's Disease Is Related to Faster Disease Progression.
    Cavaco S; Gonçalves A; Mendes A; Vila-Chã N; Moreira I; Fernandes J; Damásio J; Teixeira-Pinto A; Bastos Lima A
    Behav Neurol; 2015; 2015():976589. PubMed ID: 26136625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of the dopaminergic response in Parkinson's disease.
    Müller T; Benz S
    Parkinsonism Relat Disord; 2002 Jan; 8(3):181-6. PubMed ID: 12039429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone.
    Shan DE; Lee SJ; Chao LY; Yeh SI
    Can J Neurol Sci; 2001 Feb; 28(1):70-5. PubMed ID: 11252300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.